There are a handful of players that are pretty advanced. They're either close to getting approval for clinical trials, or they have clinical trials in process. Sinchron wants to use blood vessels as a backdoor into the brain. There's another company that might not be considered brain computer interfaces, but they want to put chips in or near your brain to treat depression.
Startups pioneering invasive and noninvasive devices that interact with the brain seek to alleviate everything from ALS symptoms to epilepsy to treatment-resistant depression. In this episode, a look at the science behind this rapidly advancing technology.
Dr. Thomas Oxley, a neurointerventionist and CEO of Synchron, gives us a tour of his lab in Brooklyn, New York, where his company is developing an implant that allows paralyzed people to control devices.
Then Bloomberg reporter Sarah McBride joins Wes for a look at other startups making these brain-computer interfaces–and where the industry goes from here.
Listen to The Big Take podcast every weekday and subscribe to our daily newsletter: https://bloom.bg/3F3EJAK
Have questions or comments for Wes and the team? Reach us at bigtake@bloomberg.net.
See omnystudio.com/listener for privacy information.